Form 4: Catalina Valencia Acquires Convertible Note in Axim Biotechnologies

Catalina Valencia, a director and 10% owner of Axim Biotechnologies, acquired a convertible note worth $156,750, which can be converted into 7,837,500 shares of common stock.

Summary

• On March 15, 2024, Catalina Valencia, a director and 10% owner of Axim Biotechnologies, acquired a convertible note with a face value of $156,750.
• The note can be converted into 7,837,500 shares of Axim Biotechnologies' common stock at a conversion price of $0.02 per share.
• The convertible note is exercisable immediately and expires on March 1, 2034.
• Following the transaction, Ms. Valencia directly owns 7,837,500 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider activity. The acquisition of a convertible note could be seen as positive, but it also carries the risk of dilution.

Positives

• The acquisition of the convertible note by a director and 10% owner could be seen as a sign of confidence in the company's future prospects.

Risks

• The conversion of the note into 7,837,500 shares could potentially dilute existing shareholders' equity.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, and 10% owners) of a publicly traded company buy or sell the company's securities. This filing provides transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may experience dilution if the convertible note is exercised.
• The transaction could signal confidence from a key insider, potentially impacting investor sentiment.

Key Dates

Keywords

Convertible Note, AXIM Biotechnologies, Catalina Valencia, Form 4, Beneficial Ownership, Director, 10% Owner